Key statistics
On Tuesday, Formycon AG (FYB:DUS) closed at 46.70, 23.54% above the 52 week low of 37.80 set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 48.35 |
---|---|
High | 48.35 |
Low | 46.40 |
Bid | 46.80 |
Offer | 48.00 |
Previous close | 47.70 |
Average volume | 527.00 |
---|---|
Shares outstanding | 17.66m |
Free float | 11.73m |
P/E (TTM) | 11.96 |
Market cap | 844.88m EUR |
EPS (TTM) | 4.00 EUR |
Data delayed at least 15 minutes, as of Nov 12 2024 18:31 GMT.
More ▼
Announcements
- EQS-News: Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange
- EQS-News: Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D
- Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
- EQS-News: Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
- EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
- EQS-News: Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
More ▼